New Approaches to the Treatment of Myelodysplasia

New Approaches to the Treatment of Myelodysplasia Alan F. List Oncologist 2002; 7(Suppl 1): 39-49 Author Information and Disclosures Target Audience: Physicians who wish to advance their current knowledge of clinical cancer medicine in acute and chronic leukemia and multiple myeloma and are involved in providing patient care in a cancer care environment. Method of Physician Participation: Read course materials, complete course quiz and evaluation form (optional). Learning Objectives After completing this course, the reader should be able to: Describe the basic biology of various leukemias, multiple myeloma, and myelodysplastic syndrome (MDS). Discuss new targeted treatment strategies for hematologic malignancies. Understand the rationale for the use of nontraditional cytotoxic agents such as arsenic trioxide in the treatment of hematologic malignancies. Examine the role of arsenic trioxide and other novel agents in early- versus accelerated-stage hematologic disease. Discuss the preclinical and clinical efficacy of arsenic trioxide and various agents in treating acute promyelocytic leukemia, MDS, and multiple myeloma. The NIH/FAES designates this educational activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

CME Activity Information Accreditation CME Instructions For Credit Privacy Statement Hardware/Software Requirements Release Date: Apr. 12, 2002 Most Recent Review: June 10, 2005* Most Recent Update: Apr. 12, 2002 Date Credit Expires: Apr. 10, 2007 Time to Complete: 1 hour Medium: Internet Online *Click here to learn more about our review process.

Click Here to return to the complete course listing of Novel Approaches to the Treatment of Advanced Hematologic Malignancies